Advances in the Development of Vaccines Against Marburg and Ebola Viruses

Overview

Journal Future Virol

Specialty Microbiology

Date 2022 Oct 27

PMID 36299498

Authors

Peter L Collins

Alexander Bukreyev

Affiliations

Soon will be listed here.

Citing Articles

Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.

Bukreyev A, Marzi A, Feldmann F, Zhang L, Yang L, Ward J Virology. 2008; 383(2):348-61.

PMID: 19010509 PMC: 2649782. DOI: 10.1016/j.virol.2008.09.030.

References

Bukreyev A, Yang L, Zaki S, Shieh W, Rollin P, Murphy B . A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol. 2006; 80(5):2267-79. PMC: 1395378. DOI: 10.1128/JVI.80.5.2267-2279.2006. View

Sullivan N, Sanchez A, Rollin P, Yang Z, Nabel G . Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000; 408(6812):605-9. DOI: 10.1038/35046108. View

Feldmann H, Jones S, Daddario-DiCaprio K, Geisbert J, Stroher U, Grolla A . Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007; 3(1):e2. PMC: 1779298. DOI: 10.1371/journal.ppat.0030002. View

Sergeev A, Lub M, Piankova O, Kotliarov L . [The efficacy of the emergency prophylactic and therapeutic actions of immunomodulators in experimental filovirus infections]. Antibiot Khimioter. 1995; 40(5):24-7. View

Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R . Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004; 78(10):5458-65. PMC: 400370. DOI: 10.1128/jvi.78.10.5458-5465.2004. View

Quiroz E, Moreno N, Peralta P, Tesh R . A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am J Trop Med Hyg. 1988; 39(3):312-4. DOI: 10.4269/ajtmh.1988.39.312. View

Volchkov V, Volchkova V, Muhlberger E, Kolesnikova L, Weik M, Dolnik O . Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science. 2001; 291(5510):1965-9. DOI: 10.1126/science.1057269. View

Geisbert T, Pushko P, Anderson K, Smith J, Davis K, Jahrling P . Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002; 8(5):503-7. PMC: 3369765. DOI: 10.3201/eid0805.010284. View

Sullivan N, Geisbert T, Geisbert J, Shedlock D, Xu L, Lamoreaux L . Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006; 3(6):e177. PMC: 1459482. DOI: 10.1371/journal.pmed.0030177. View

10.

Yang Z, Wyatt L, Kong W, Moodie Z, Moss B, Nabel G . Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol. 2002; 77(1):799-803. PMC: 140625. DOI: 10.1128/jvi.77.1.799-803.2003. View

11.

Weiss B, Wright R, Schlesinger S . Complementation between Sindbis viral RNAs produces infectious particles with a bipartite genome. Proc Natl Acad Sci U S A. 1991; 88(8):3253-7. PMC: 51424. DOI: 10.1073/pnas.88.8.3253. View

12.

Kobinger G, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F . Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2005; 346(2):394-401. DOI: 10.1016/j.virol.2005.10.042. View

13.

Jaax N, Jahrling P, Geisbert T, Geisbert J, Steele K, McKee K . Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet. 1995; 346(8991-8992):1669-71. DOI: 10.1016/s0140-6736(95)92841-3. View

14.

Johnson E, Jaax N, White J, Jahrling P . Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol. 1995; 76(4):227-36. PMC: 1997182. View

15.

Stanford M, McFadden G, Karupiah G, Chaudhri G . Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol Cell Biol. 2007; 85(2):93-102. DOI: 10.1038/sj.icb.7100033. View

16.

Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A . Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 1998; 251(1):28-37. DOI: 10.1006/viro.1998.9367. View

17.

Bukreyev A, Rollin P, Tate M, Yang L, Zaki S, Shieh W . Successful topical respiratory tract immunization of primates against Ebola virus. J Virol. 2007; 81(12):6379-88. PMC: 1900097. DOI: 10.1128/JVI.00105-07. View

18.

Enterlein S, Volchkov V, Weik M, Kolesnikova L, Volchkova V, Klenk H . Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30. J Virol. 2005; 80(2):1038-43. PMC: 1346851. DOI: 10.1128/JVI.80.2.1038-1043.2006. View

19.

Pushko P, Parker M, Ludwig G, Davis N, Johnston R, Smith J . Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology. 1998; 239(2):389-401. DOI: 10.1006/viro.1997.8878. View

20.

Sullivan N, Geisbert T, Geisbert J, Xu L, Yang Z, Roederer M . Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003; 424(6949):681-4. PMC: 7095492. DOI: 10.1038/nature01876. View